메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Neurophet Publishes Clinical Validation Results of 'Neurophet AQUA' in Annals Academy of Medicine Singapore

- Clinical study conducted at the Dementia Research Centre, Nanyang Technological University, Singapore, involving Southeast Asian participants - Expert level accuracy, while significantly reducing analysis time for white matter hyperintensity and gray matter volume SEOUL, South Korea, Sept. 30, 2025 -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on the 30th that the results of a clinical study validating the clinical efficacy of its brain neurodegeneration
- 김갑성 기자
- 2025-09-30 21:00
Data4Life and EvidNet form strategic partnership to advance federated real-world evidence generation

[ 메디채널 김갑성 기자 ] Data2Evidence meets FeederNet: Joining forces for scalable, standardized, and responsible health research infrastructure SEOUL, South Korea and POTSDAM, Germany, Sept. 30, 2025 -- Nonprofit digital health organization Data4Life and South Korea's leading federated research platform EvidNet today announced a strategic partnership to co-develop a global infrastructure for federated real-world evidence (RWE) generation. The collaboration will combine the technological strengths and research networks of both organizations to enable high-quality, privacy-preserving, and sca
- 김갑성 기자
- 2025-09-30 16:00
InnoMax MedTech Chairman Jackson Shih: Bridging Technical Gaps with End-to-End Services for Medical Device Manufacturers

SHANGHAI, Sept. 30, 2025 -- From September 24 to 26, InnoMax Medical Technology Co., Ltd. (InnoMax MedTech) featured its portfolio of proprietary products at 2025 Medtec China, spanning medical imaging and respiratory care. Among them was the company's proprietary Portable Mesh Nebulizer, alongside a portable oxygen concentrator, AI-enabled sleep-assist device, injection pens, and blood glucose meters, drawing strong interest from healthcare and medtech professionals. "Our product portfolio spans several key healthcare segments—from in-vitro diagnostics and medical imaging to resp
- 김갑성 기자
- 2025-09-30 11:03
Novartis Singapore and the Singapore Heart Foundation Launch 'Beat the Block' Campaign to Raise Awareness of High Blood Cholesterol

Local survey reveals critical misconceptions and gaps in blood cholesterol management among people living in Singapore. Almost one in three deaths in Singapore is attributed to cardiovascular disease, underscoring the urgent need to improve blood cholesterol management.[1] Beat the Block was launched to raise awareness of optimal low-density lipoprotein cholesterol (LDL-C) levels, a critical starting point in managing heart health. SINGAPORE, Sept. 30, 2025 -- Novartis Singapore (Novartis) and the Singapore Heart Foundation (SHF) have jointly launched Beat the Block —
- 김갑성 기자
- 2025-09-30 10:00
Johnson & Johnson Launches "Dual Control" Campaign in Asia Pacific to Empower Patients with IBD to Balance Disease Management and Dreams

New IBD research shows that, even during clinical remission, people living with Crohn's disease continue to experience greater work impairment than the general population The new campaign aims to empower patients to take dual control of disease management and life aspirations by striving for endoscopic remission through shared decision-making SINGAPORE, Sept. 30, 2025 -- Johnson & Johnson today launched the Dual Control campaign in Asia Pacific to raise awareness about the importance of enhanced shared decision-making and how it can help patients achieve sustained e
- 김갑성 기자
- 2025-09-30 10:00
Pier 88 Health and Theranica Announce China NMPA Approval of the Nerivio® REN wearable for Acute Treatment of Migraine

First and Only REN-Based Migraine Treatment Approved in China BEIJING and NETANYA, Israel, Sept. 30, 2025 -- Pier 88 Health, a digital health company dedicated to reshaping chronic pain management and bringing breakthrough global medical innovations to Greater China, and Theranica, a prescribed digital therapeutics company, today announced that the Nerivio® REN wearable, a novel treatment of migraine, has received regulatory approval from China's National Medical Products Administration (NMPA). The registration certificate (国械注进20252090343), issued on August 11, 2025
- 김갑성 기자
- 2025-09-30 09:00
카탈렌트, 플로리다주 탬파에서 새로 이전한 본사 개소식 진행

이번 이전은 인근의 세인트피터즈버그에 있는 오랜 제조 시설을 기반으로 플로리다 내 전략적 확장의 일환으로 결정되었다. 혁신, 협업, 성장을 지원하도록 설계된 새로운 본사 탬파, 플로리다주 2025년 9월 30일 -- 제약 및 의료 분야의 기업과 손잡고 전 세계 환자를 위해 더 효과적인 치료법을 개발하고 제공하는 데 일조하는 굴지의 기업인 카탈렌트(Catalent, Inc.)가 오늘 플로리다주 탬파에 새로운 본사를 개소한다고 발표했다. 첨단 설비를 갖춘 본사는 혁신, 협업, 우수성을 콘셉트로 설계되었으며, 독보적인 서비스와 환자 우선 주의를 통해 제약, 생명 공학, 소비자 건강 분야에 종사하는 기업을 위해 가치를 창출하려는 카탈렌트의 의지를 뒷받침하게 된다. 올해 초에 카탈렌트는 뉴저지주 서머셋에 있는 기존의 본사를 이전하여 뉴저지주 브리지워터에 지사를, 탬파에 새로 본사를 둘 예정이라고 발표한 바 있다. 탬파로의 이전은 플로리다주 중심의 전략적 확충 차원에서 결정된 사안이다. 세인트피터즈버그에는 카탈렌트가 오래전부터 플로리다주에서 입지를 유지하는 데 활용해 온 50만 제곱피트(약 46,000㎡) 크기의 공장이 있다. 참
- 김갑성 기자
- 2025-09-30 09:00
Full-Life Technologies Announces US$77 Million Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Manufacturing Capabilities

[ 메디채널 김갑성 기자 ] Series C led by Junson Capital along with new investor syndicate and existing shareholders Funding will further advance Full-Life's global radiopharmaceutical pipeline and manufacturing capabilities in Belgium Additional debt financing provides an alternative financing solution for Full-Life's future development CHENGDU, China and GEMBLOUX, Belgium, Sept. 30, 2025 -- Full-Life Technologies ("Full-Life", the "Company"), a fully-integrated global radiotherapeutics company, today announced the completion of US$77 million financing, comprised of
- 김갑성 기자
- 2025-09-30 08:00
Locus Cell's Zhubei Smart GMP Facility Secures First International Phase III CDMO Manufacturing MOU with Cambium Bio

TAIPEI, Sept. 30, 2025 -- Locus Cell (TWSE: 6891), a leading regenerative medicine CDMO in Taiwan, announced it has signed a Memorandum of Understanding (MOU) with Australia-based Cambium Bio (ASX: CMB). Under the agreement, Cambium will entrust Locus Cell with the contract development and manufacturing (CDMO) of Elate Ocular® -related. Elate Ocular®, a Phase III dry eye disease therapy currently under clinical trials in Taiwan, the U.S., and Australia. The technology originates from Cambium's parent company, Zheng Yang Biomedical Technology Co., Ltd. Jiunn-Rong Chiou,
- 김갑성 기자
- 2025-09-30 07:00
United Imaging Announces the uDR® Aurora CX

[ 메디채널 김갑성 기자 ] "Designed for Freedom," the newly FDA-cleared system will be showcased at RSNA. HOUSTON, Sept. 30, 2025 -- United Imaging has announced its new digital radiography system, uDR Aurora CX, which is intended to introduce computer vision, automation, and AI diagnostics into one of the most widely used imaging modalities in healthcare. At the core of uDR Aurora CX is the uVERA platform which provides vision enabled robotics and AI into United Imaging's digital radiography portfolio. The uDR Aurora comes with two uAI® Vision Cameras integrated into th
- 김갑성 기자
- 2025-09-30 00:00

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-10-19_SUN

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 19일 03시 20분